Results 1 to 10 of about 473,693 (291)

Anti-SARS-CoV-2 Spike IgG Following Injection of the Third Dose Vaccine: A Systematic Review With Meta-Analysis of Heterologous Versus Homologous Vaccination [PDF]

Frontiers in Public Health, 2023
BackgroundThe mass vaccination is a key strategy to prevent and control the coronavirus disease 2019 (COVID-19) pandemic. Today, several different types of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed ...
Fahimhe Attarian, Mohammad-Shafi Mojadadi, Seyed Alireza Javadinia   +2 more
exaly   +4 more sources

Differential functional immune recall across homologous and heterologous COVID-19 vaccination regimens [PDF]

Frontiers in Immunology
IntroductionUnderstanding how different COVID-19 vaccine combinations shape long-term immunity is essential for improving durability and guiding booster strategies.
Naim Che-Kamaruddin, Naim Che-Kamaruddin, Jefree Johari, Hasmawati Yahaya, Nurhafiza Zainal, Huy C. Nguyen, Robert D. Hontz, Andrew G. Letizia, Sazaly AbuBakar   +8 more
doaj   +3 more sources

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +3 more sources

Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms [PDF]

Vaccines, 2022
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination.
Anna Parys, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter, Kristien Van Reeth   +6 more
doaj   +2 more sources

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination

Journal of Infection and Public Health, 2023
Background: The ongoing COVID-19 pandemic has seen the emergence of numerous novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
Jaeeun Yoo, Younjeong Kim, Yu mi Cha, Jaewoong Lee, Yeon Jeong Jeong, Si-Hyun Kim, Lisa L. Maragakis, Seungok Lee   +7 more
doaj   +3 more sources

Dynamics of Humoral and Cellular Immune Responses After Homologous and Heterologous SARS-CoV-2 Vaccination With ChAdOx1 nCoV-19 and BNT162b2

EBioMedicine, 2022
Summary: Background: Vaccines are an important means to overcome the SARS-CoV-2 pandemic. They induce specific antibody and T-cell responses but it remains open how well vaccine-induced immunity is preserved over time following homologous and ...
Kilian Schober, Nina Körber, Matthias Tenbusch   +2 more
exaly   +3 more sources

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Scientific Reports, 2023
In this single-center observational study with 1,206 participants, we prospectively evaluated SARS-CoV-2-antibodies (anti-S RBD) and vaccine-related adverse drug reactions (ADR) after basic and booster immunization with BNT162b2- and ChAdOx1-S-vaccines ...
Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, Katharina Graf, Sebastian Appelbaum, Reinhard Koß, Christian Theis, Zewarudin Zia, Jürgen Tebbenjohanns, Serge C. Thal, Michael Dedroogh   +10 more
doaj   +1 more source

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity

Frontiers in Immunology, 2023
Currently available COVID-19 vaccines include inactivated virus, live attenuated virus, mRNA-based, viral vectored and adjuvanted protein-subunit-based vaccines.
Larissa Henze, Larissa Henze, Julian Braun, Julian Braun, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Lil Meyer-Arndt, Karsten Jürchott, Karsten Jürchott, Maike Schlotz, Janine Michel, Marica Grossegesse, Maike Mangold, Maike Mangold, Manuela Dingeldey, Manuela Dingeldey, Beate Kruse, Beate Kruse, Pavlo Holenya, Norbert Mages, Norbert Mages, Norbert Mages, Ulf Reimer, Maren Eckey, Karsten Schnatbaum, Holger Wenschuh, Bernd Timmermann, Florian Klein, Florian Klein, Florian Klein, Andreas Nitsche, Claudia Giesecke-Thiel, Lucie Loyal, Lucie Loyal, Andreas Thiel, Andreas Thiel   +36 more
doaj   +1 more source

Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines

Vaccines, 2022
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens.
Ulrika Marking, Sebastian Havervall, Nina Greilert-Norin, Henry Ng, Kim Blom, Peter Nilsson, Mia Phillipson, Sophia Hober, Charlotta Nilsson, Sara Mangsbo, Wanda Christ, Jonas Klingström, Max Gordon, Mikael Åberg, Charlotte Thålin   +14 more
doaj   +1 more source

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial

Frontiers in Immunology, 2023
Background/PurposeOptimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination.
Leyla Sharifi Aliabadi, Manoochehr Karami, Manoochehr Karami, Maryam Barkhordar, Seyed Saeed Hashemi Nazari, Amir Kavousi, Mohammad Ahmadvand, Mohammad Vaezi, Mohammad Vaezi   +8 more
doaj   +1 more source